Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT04890067
Recruiting Observational

Observational Study in Localized Osteosarcoma

NCT04890067 · tracked via the Priya Life Science Italy tracker
Sponsor
Italian Sarcoma Group
Phase
Observational
Started
2021-07-30
Last updated
2026-09-02

Condition(s) studied

Localized Osteosarcoma

Investigational drug(s) / intervention(s)

Treatment of Osteosarcoma according the AIEOP/ISG OS 2021 recommendations (includes drugs, surgery, radiotherapy or any other received treatments)

Treatment of Osteosarcoma according the AIEOP/ISG OS 2021 recommendations (includes drugs, surgery, radiotherapy or any other received treatments): This observational study collects all the treatments received by the patients according according the AIEOP/ISG OS 2021 and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments

Study summary

Observational prospective trial aimed to collect the collect demographic, clinical, surgical, pathological and molecular characteristics and treatment from patients affected by localized OsteoSarcoma (OS) treated according the AIEOP/Italian Sarcoma Group (ISG) OS 2021

Eligibility

Sex
ALL
Min age
—
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of high grade OS of the extremities * Age at diagnosis ≤ 40 years at the time of diagnosis * Localized disease (skip metastases are allowed) * Adequate organ function according the AIEOP/ISG OS 2021 recommendation * Patients or parents oe guardians of minors who have given their written informed consent to participate in the study Exclusion Criteria: * Presence of metastases * Diagnosis of periosteal OS, of parosteal OS or secondary OS * Any medical condition which can not allowed the use of the treatments recommended by AIEOP/ISG OS 2021

Primary outcome measure(s)

  • 5 years Event Free Survival (EFS) — 5 years
    Onset of any event (an event is the defined as disease recurrence, death for disease or any other cause)

Trial sites (16)

FacilityCityRegionStatus
Centro di Riferimento Oncologico - Unit of Medical Oncology Aviano Pordenone Recruiting
Sandra Aliberti Candiolo Torino Recruiting
IRCCS materno infantile Burlo Garofolo Trieste T Recruiting
Azienda Ospedaliero Universitaria Consorziale Policlinico - Bari Bari Italy Recruiting
IRCCS Istituto ortopedico Rizzoli Bologna Italy Recruiting
A.O. Universitaria Policlinico S. Orsola Malpighi di Bologna Bologna Italy Recruiting
AUO Policnico G. Rodolico San Marco Catania Italy Recruiting
A.O. Universitaria Meyer Florence Italy Recruiting
Istituto Giannina Gaslini Genova Italy Recruiting
Fondazione IRCCS INT Milano SC Pediatria Oncologica Milan Italy Recruiting
FONDAZIONE IRCCS Istituto Nazionale dei Tumori Milan Italy Recruiting
Azienda Ospedaliera di Padova UOC Oncoematologia Pediatrica Padova Italy Recruiting
ARNAS P. O. "Civico e Benfratelli" Palermo Italy Recruiting
Azienda Ospedaliero-Universitaria Pisana Pisa Italy Recruiting
Istituti Fisioterapici Ospitalieri di Roma Roma Italy Recruiting
Ospedale Pediatrico Bambin Gesu' Roma Italy Not Yet Recruiting

More Italian Sarcoma Group trials in Italy

Study on Clinical Features and Outcomes of Breast Sarcoma Recruiting
Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease Recruiting
Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS Recruiting
Observational Study on Skeletal Ewing's Sarcoma Recruiting
Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04890067 on ClinicalTrials.gov ↗ ← All trials in Italy